G-protein coupled receptors: SAR analyses of neurotransmitters and antagonists

Journal of Clinical Pharmacy and Therapeutics

Volumn 29, Issue 3, 2004, Pages 279-298

  Kuo, C L ^a   Wang, R B ^b   Shen, L J ^a   Lien, L L ^a   Lien, E J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

G protein coupled receptors; Neurotransmitter agonists and antagonists; SAR

Indexed keywords

ACETYLCHOLINE; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; HISTAMINE; HISTAMINE AGONIST; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; NORADRENALIN; RECEPTOR BLOCKING AGENT; SEROTONIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG;

ARTICLE; BINDING AFFINITY; CARDIOSELECTIVITY; DIPOLE; DRUG IDENTIFICATION; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; EQUILIBRIUM CONSTANT; HUMAN; HYDROPHOBICITY; MOLECULAR WEIGHT; NONHUMAN; PARTITION COEFFICIENT; PHARMACOLOGICAL BLOCKING; PHYSICAL CHEMISTRY; PROTEIN DOMAIN; PROTEIN STRUCTURE; SEROTONIN UPTAKE; STEREOCHEMISTRY; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADRENERGIC AGONISTS; ADRENERGIC ANTAGONISTS; CHEMISTRY, PHYSICAL; CHOLINERGIC AGONISTS; CHOLINERGIC ANTAGONISTS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HISTAMINE AGONISTS; HISTAMINE ANTAGONISTS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NEUROTRANSMITTER AGENTS; RECEPTORS, ADRENERGIC; RECEPTORS, CHOLINERGIC; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3142512601     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2004.00563.x     Document Type: Article

References (31)

1. Albert A. (1965) Selective toxicity, 3rd edn. New York: John Wiley, 1-394.
2. Schueler FW. (1960) Chemobiodynamics and drug design. New York: McGraw Hill, 140.
3. Ehrenpreis S, Fleish JA, Mittag TW (1969) Approaches to the molecular nature of pharmacological receptors. Pharmacological Reviews, 21, 131-181.
4. Lien EJ (1987) SAR side effects and drug design. New York and Basel: Marcel Dekker, Inc., 1-368.
5. Lameh J, Cone RI, Maeda S et al. (1990) Structures and function of G-protein copuled receptors. Pharmaceutical Research, 7, 1213-1221.
6. Liu QR, Mandian S, Nelson H, Nelson N (1992) A family of genes encoding neurotransmitter transporters. Proceedings of the National Academy of Sciences of the USA, 89, 6639-6643.
7. 2-purinergic receptors for extracellular ATP and other nucleotides. American Journal of Physiology, 265, C577-C606.
8. Gottesman MM, Pastan I (1993) Biochemistry of multiple drug resistance mediated by the multidrug transporter. Annual Review of Biochemistry, 62, 385-427.
9. Watson S, Arkinstall S (1994) The G-protein linked receptor facts book. New York, London: Academic Press, 1-117.
10. Palmer TM, Stiles GL (1995) Review: neurotransmitter receptors IV. Andenosine receptors. Neuropharmacology, 34, 683-694.
11. Zhang X, Collins KL, Greenberger LM (1995) Functional evidence that transmembrane and the loop between transmembrane 11 and 12 form part of the drug-binding domain in P-glycoprotein encoded by MDRI. Journal of Biological Chemistry, 270, 5541-5548.
12. Harden TK, Boyer JL, Nicholas RA (1995) P2-purinergic receptors: subtype-associated signaling responses and structure. Annual Review of Pharmacology and Toxicology, 35, 541-579.
13. Ross EM (1996) Chapter 2. Pharmacodynamics. Mechanisms of drug action and the relationship between drug concentration and effect. In: Hardman JG, Limbrid LE, eds. Goodman & Gilman's the pharmacological basis of therapeutics, 9th edn. New York: McGraw Hill, 29-11.
14. + neurotransmitter transporters. Journal of Neurochemistry, 71, 1785-1803.
15. Seelig A (1998) A general pattern for substrate recognition by p-glycoprotein. European Journal of Biochemistry, 251, 252-261.
16. Surendran N, Covits KMY, Han HK et al. (1999) Evident for overlapping substrate specificity between large neutral amino acid (LNAA) and dipeptide (hPEPT 1) transporters for PD 158473, and NMDA antagonist. Pharmaceutical Research, 16, 391-395.
17. Seelig A, Blatter XL, Wohnsland F (2000) Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. International Journal of Clinical Pharmacology and Therapeutics, 38, 111-121.
18. Walsh P (2000) Physicians' desk reference, 55th edn. New Jersey: Medical Economics Montvale, 1437-1439.
19. Chillaron J, Roca R, Valencia A, Zorzano A, Palacin M (2001) Herteromeric amino acid transporters: biochemistry, genetics, and physiology. American Journal of Physiology, 281, F995-F1018.
20. Miyazawa A, Fujiyoshi Y, Unwin N (2003) Structure and gating mechanism of the acetylcholine receptor pore. Nature, 423, 949-955.
21. Walsh PM (2003) Physicians' desk reference, 57th edn. New Jersey: Thomson PDR at Montvale.
22. O'Neil MJ (2001) The Merck index, 13th edn. Whithouse Station, New Jersey: Meek & Co., Inc.
23. Biobyte Corp. Clog P, Version 4.0, 201 W Fouth St Suite 204, Claremont, CA 91711: Biobyte Corp.
24. Hypercube, Inc. HyperChem for window, Version 5.0, 1115 NW, 4TH Street, Gainesville, FL, 32601: Hypercube, Inc.
25. MicroCal Software, Inc. MicroCal origin, Version 6.0, One Roundhouse Plaza, Northampton, MA, 01060: MicroCal Software, Inc.
26. 2-values of a series of compounds in a histaminic and a cholinergic system. European Journal of Pharmacology, 44, 251-270.
27. Agrawal VK, Sachan S, Khadikar PV (2000) QSAR studies on antihistaminic activity of some thiazolidine-4-ones. Acta Pharm, 50, 281-290.
28. Lien EJ, Gao H, Lien LL (1994) In search of ideal antihypertensive drugs: progress in five decades. Progress in Drug Research, 43, 43-86.
29. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of Schizophrenia. Synapse, 1, 133.
30. Katzung BG (1995) Basic & clinical pharmacology, 6th edn. Norwalk, Connecticut: Appleton & Lange, 436.
31. Hurley JH, Bloen LJ, Pavalko F, Liu J, Tian M, Simon JR, Yu L (1999) Structure-function studies of the eight hydrophobic domain of a serotonin receptor. Journal of Neurochemistry, 72, 413-421.